Prevalence and Progress of Coronavirus in Hemodialysis Patients

Yıl 2021, , 144 - 149, 30.09.2021

Can Hüzmeli , Mustafa Gür , Ali Borazan

https://doi.org/10.47565/ndthdt.2021.42

Öz

The coronavirus (COVID 19), which first appeared in the Wuhan region of China towards the end of 2019, was later detected in many countries of the world and was declared a pandemic by the World Health Organization. Hemodialysis patients are in the high-risk group with their constant visits to health centers, weak immune immunity, and accompanying comorbidities. In this study, we tried to evaluate the prevalence and clinical course of COVID 19 in hemodialysis patients.
Material-Method: Hemodialysis patients who had Covid 19 between September 2020 and December 2020 were included in the study. Diagnosis of Covid 19 errors was diagnosed by positive PCR test or thorax computed tomography.
Results: A total of 984 patients were screened in the study, of which 298 were found to have had Covid 19. The prevalence of patients who had Covid 19 was 30.2%. The mean age of the patients who had Covid 19 was 62.11±13.4 (15-91). The patients were 189 men and 109 women. The mortality rate of the patients was 22.5% (67 patients). While the mean age of the patients who survived Covid 19 was 61.2±13.6, the mean age of the patients who died was 65.1±12.2. A statistically significant correlation was found between advanced age, increase in C-reactive protein (CRP), increase in aspartate aminotransferase, and increase in lactate dehydrogenase with mortality. The most common symptoms were cough and fatigue.
Conclusion: In our study, the prevalence of covid 19 was found to be 30.2%. The mortality rate was found to be 22.5%. A significant correlation was found between advanced age, increased CRP and covid 19-related mortality.

Anahtar Kelimeler

Covid 19, Hemodialysis, Mortality

Hemodiyaliz Hastalarında Koronavirüs Prevalansı ve Klinik Seyri/ Prevalence and Progress of Coronavirus in Hemodialysis Patients

Öz

İlk defa 2019 yılının sonuna doğru Çin’in Wuhan bölgesinde baş gösteren coronavirüs (COVİD 19), daha sonra da dünyanın pek çok ülkesinde saptanmaya başlamış ve Dünya Sağlık Örgütü tarafından pandemi ilan edilmiştir. Hemodiyaliz hastaları, sürekli sağlık merkezine gitmeleri, immun bağışıklığı zayıf olması ve eşlik eden komorbideteler ile yüksek riskli grupta yer almaktadır. Bu çalışmada hemodiyaliz hastalarında COVİD 19 prevalansı ve klinik seyrini değerlendirmeye çalıştık.
Materyal-Metod: Çalışmaya Eylül 2020 ile Aralık 2020 arasında Covid 19 geçiren hemodiyaliz hastalar alındı. Covid 19 hastalarının tanısı PCR testi pozitif veya toraks bilgisayarlı tomografi ile konfirme edildi.
Bulgular: Çalışmada toplam 984 hasta tarandı, bunların 298’inin Covid 19 geçirdiği saptandı. Covid 19 geçiren hastaların prevalansı %30,2 saptandı. Covid 19 geçiren hastaların yaş ortalaması 62,11±13,4 (15-91) olarak tespit edildi. Hastaların 189 erkek ve 109 kadındı. Hastaların mortalite oranı %22,5 (67 hasta) tespit edildi. Covid 19 atlatan hastaların yaş ortalaması 61,2±13,6 iken ölen hastaların yaş ortalaması 65,1±12,2 olarak saptandı. İleri yaş, C reaktif protein (CRP) artışı, aspartat aminotransferaz artışı ve laktat dehidrogenaz artışı ile mortalite arasında istatistiksel olarak anlamlı bir ilişki saptandı. En sık görülen semptomu öksürük ve halsizlik olarak saptandı.
Sonuç: Çalışmamız da covid 19 prevalansı %30,2 saptandı. Mortalite oranı %22,5 olarak saptandı. İleri yaş, CRP artışı ile covid 19 bağlı mortalite arasında anlamlı ilişki tespit edildi.

Anahtar Kelimeler

Covid 19, Hemodiyaliz, Mortalite

Kaynakça

• 1. Tyrrell DA, Bynoe ML. Cultivation of viruses from a high proportion of patients with colds. Lancet 1966;1:76–77. doi: 10.1016/s0140-6736(66)92364-6
• 2. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-273. https://doi.org/10.1038/s41586-020-2012-7
• 3. Velavan TP, Meyer CG. The COVID‐19 epidemic. Tropical Medicine & International Health. 2020;25(3):278. doi: 10.1111/tmi.13383
• 4. Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, et al. COVID‐19 diagnosis and management: a comprehensive review. Journal of Internal Medicine. 2020;288(2):192-206. PMCID: DOI: 10.1111/joim.13091
• 5. Berlin DA, Gulick RM, Martinez FJ. Severe covid-19. New England Journal of Medicine. 2020;383(25):2451-2460. doi: 10.1056/NEJMcp2009575
• 6. Ciotti M, Angeletti S, Minieri M, Giovannetti M, Benvenuto D, Pascarella S, etal. COVID-19 outbreak: an overview. Chemotherapy. 2019;64(5-6):215-223. doi: 10.1159/000507423
• 7. Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, et al. COVID‐19 diagnosis and management: a comprehensive review. Journal of Internal Medicine. 2020;288(2):192-206. doi: 10.1111/joim.13091
• 8. Ikizler TA. COVID-19 and dialysis units: what do we know now and what should we do?. American Journal of Kidney Diseases. 2020;76(1):1. doi: 10.1053/j.ajkd.2020.03.008
• 9. Gallieni M, Sabiu G, Scorza D. Delivering safe and effective hemodialysis in patients with suspected or confirmed COVID-19 infection: a single-center perspective from Italy. Kidney360. 2020; 1 (5): 403-409.doi: https://doi.org/10.34067/KID.0001782020
• 10. Fisher M, Yunes M, Mokrzycki MH, Golestaneh L, Alahiri E, Coco M. Chronic hemodialysis patients hospitalized with COVID-19-short-term outcomes in Bronx, New York. Kidney360. 2020; 1 (8): 755-762. doi: https://doi.org/10.34067/KID.0003672020
• 11. Stefan G, Mehedinti AM, Andreiana I, Zugravu AD, Cinca S, Busuioc R, et al. Clinical features and outcome of maintenance hemodialysis patients with COVID-19 from a tertiary nephrology care center in Romania. Renal Failure. 2021;43(1):49-57. doi: 10.1080/0886022X.2020.1853571
• 12.Turgutalp K, Ozturk S, Arici M, Eren N, Gorgulu N, Islam M, et al. Determinants of mortality in a large group of hemodialysis patients hospitalized for COVID-19. BMC Nephrology, 2021;22(1):1-10. doi: 10.1186/s12882-021-02233-0
• 13.Aydin Bahat K, Parmaksiz E, Sert S. The clinical characteristics and course of COVID‐19 in hemodialysis patients. Hemodialysis International. 2020:24(4);534-540. https://doi.org/10.1111/hdi.12861
• 14.Ma Y, Diao B, Lv X, Zhu J, Liang W, Liu L, et al. 2019 novel Coronavirus disease in hemodialysis (HD) patients: Report from one HD center in Wuhan, China. MedRxiv.2020. doi: https://doi.org/10.1101/2020.02.24.20027201
• 15.Xiong F, Tang H, Liu L, Tu C, Tian JB, Lei CT, et al. Clinical characteristics of and medical interventions for COVİD-19 in hemodialysis patients in Wuhan, China. Journal of the American Society of Nephrology. 2020;31 (7):1387-1397. doi: https://doi.org/10.1681/ASN.2020030354
• 16. 16.Kliger AS, Silberzweig J. COVID-19 and Dialysis Patients: Unsolved Problems in Early 2021. Journal of the American Society of Nephrology. 2021:32(5);1018-1020. doi: 10.1681/ASN.2020121766
• 17. Stock da Cunha T, Gomá-Garcés E, Avello A, Pereira-García M, Mas-Fontao S, Ortiz A, et al. The spectrum of clinical and serological features of COVID-19 in urban hemodialysis patients. Journal of Clinical Medicine.2020;9(7):2264. doi: 10.3390/jcm9072264
• 18.Mazzoleni L, Ghafari C, Mestrez F, Sava R, Bivoleanu E, Delmotte P, et al. COVİD-19 outbreak in a hemodialysis center: a retrospective monocentric case series. Canadian Journal of Kidney Health and Disease. 2020;7:2054358120944298. doi: 10.1177/2054358120944298.
• 19. Pio-Abreu A, do Nascimento MM, Vieira MA, de Menezes Neves PDM, Lugon JR, Sesso R. High mortality of CKD patients on hemodialysis with COVID-19 in Brazil. Journal of Nephrology. 2020;33(5):875-877. doi: 10.1007/s40620-020-00823-z
• 20.Tayebi Khosroshahi H, Mardomi A, Niknafs B, Farnood F, Shekarchi M, Salehi S, et al. Current status of COVID‐19 among hemodialysis patients in the East Azerbaijan Province of Iran. Hemodialysis International. 2021;25(2): 214-219. doi: 10.1111/hdi.12907